Euretos

Euretos

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $6.2M

Overview

Euretos is a private, revenue-generating AI/ML platform company founded in 2012 and headquartered in Utrecht, Netherlands. It has developed a sophisticated biological knowledge graph platform that integrates diverse data sources to accelerate target discovery, validation, and assessment for biopharma clients. The company has a proven track record, with its platform and services having contributed to approved drugs and active clinical trials across several therapeutic areas for multiple biopharma partners.

OncologyAutoimmune DiseasesGastrointestinal DiseasesNeurological DiseasesMetabolic Diseases

Technology Platform

AI-powered biological knowledge graph platform that integrates literature, patents, experimental data, and real-world patient data. It features predictive ML models for gene-disease associations, multi-criteria target ranking, single-cell expression analysis, and workflows for target discovery and assessment.

Funding History

2
Total raised:$6.2M
Series A$5M
Seed$1.2M

Opportunities

The accelerating adoption of AI/ML in pharmaceutical R&D to combat declining productivity presents a massive growth opportunity.
Euretos's proven impact on clinical programs serves as a powerful validation to secure new enterprise clients.
Expansion into new application areas like biomarker discovery or digital pathology integration could further broaden its market.

Risk Factors

Intense competition from other AI-driven drug discovery platforms and large tech entrants risks commoditization.
The platform's value is highly dependent on the quality and licensing of underlying data, posing a continuous operational and financial challenge.
Slower enterprise sales cycles in the pharma industry could hinder rapid scaling.

Competitive Landscape

Euretos competes in the crowded AI-for-drug-discovery market against pure-play peers like BenevolentAI, Exscientia, and Recursion, as well as informatics giants like Elsevier and IQVIA. Its differentiation lies in its integrated knowledge graph approach, focus on user-friendly workflows for researchers, and a demonstrated track record of contributing to clinical-stage outcomes.